MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (December 2016)
30 slides from MabVax Therapeutics's investor presentation, Dec 7, 2016

Slide 1: MabVax Therapeutics Corporate Presentation
NASDAQ: MBVX NY/ | MabVax therapeutics Immuno-Oncology Company Developing Products from the Human Immune Response to Cancer J. David Hansen President and CEO, co-Founder Corporate Presentation December 2016

Slide 2: Disclaimer: Forward Looking Statements
DISCLAIMER Forward Looking Statements ‘This presentation contains forward-looking statements and projections. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy an

Slide 3: Key Highlights — Product Development / Milestones
KEY HIGHLIGHTS — PRODUCT DEVELOPMENT/ MILESTONES ¢@ HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies — Integrated approach to development of a companion diag

Slide 4: Key Highlights — Corporate and Financial
KEY HIGHLIGHTS — CORPORATE AND FINANCIAL V Uplisted to Nasdaq Capital Market Effective August 17th @ Increased visibility for investors Significantly increased liquidity V Closed $9.4M financing @ Underwritten offering by Laidlaw @ Lead by OPKO and Dr. Frost along with support from existing investor

Slide 5: MabVax's Discovery Platform
MABVAX’S DISCOVERY PLATFORM: THERAPIES DERIVED FROM THE NATURAL HUMAN IMMUNE RESPONSE KI) \l- Aa Focused Discovery Highly efficient screening * Fully human antibodi against pre-identified targets natural advantages; target ty while minimizi ctivity and immunogenicity cination drives specific immune

Slide 6: MabVax Has Rich Pipeline of Product Candidates
MABVAX HAS RICH PIPELINE OF PRODUCT CANDIDATES Commercial Antibody Programs Indication Collaborators. Discovery Pre-IND Phase 1 Phase 2 Rie Therapeutic MVT-5873 Metastatic NIH, Cancers SCRI, Pathcon PET-Imaging Pancreatic & GI MSKCC, ww Cancers SCRI, Patheon Radioimmunotherapy MVT-1075 ee MSKCC ww P

Slide 7: Discovery of Lead Clinical Development Candidate HuMab 5B1 Antibody
DISCOVERY OF LEAD CLINICAL DEVELOPMENT CANDIDATE HUMAB 5B1- ANTIBODY TARGETING SIALYL LEWIS A ANTIGEN Aoce and coc activity « HuMab-5B1 derived from a patient vaccinated with sees MabVax vaccine licensed from MSKCC Internation Patients repeatedly vaccinated to drive immune © Sialy! Lewis a (6Le*) y

Slide 8: Sialyl Lewis A as a Viable Target for Cancer Therapeutics
SIALYL LEWIS: — AS A VIABLE TARGET FOR CANCER THERAPEUTICS @ Sialyl Lewis A antigen (SsLEA or CA19-9) is the most frequently utilized and only validated serum marker for assessment of pancreatic cancers @ Aberrant glycosylation results in expression of sLe* and facilitates tumor proliferation, invas

Slide 9: MabVax's Preclinical Technical Development Criteria for a Strong Product Platform
MABVAX’S PRECLINICAL TECHNICAL DEVELOPMENT CRITERIA FOR A STRONG PRODUCT PLATFORM ‘Targeting cancer cell Binds tightly to target cell Cancer cell killing Does not target normal cells Combined with chemo therapy Ability to attach additional agents Benign side effect profile in animal toxicology studi

Slide 10: Integrated Development Strategy to Maximize Antibody Value Proposition
INTEGRATED DEVELOPMENT STRATEGY TO MAXIMIZE ANTIBODY VALUE PROPOSITION Natural fully human IgG1 antibody Relies cytotoxic activity for efficacy Early safety and tolerability established PET agent conjugated to natural IgG1 antibody Antibody is targeting agent and accumulates on tumor PET scan images

Slide 11: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMAB-5B1 ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer ® A. Pancreatic ductal adenocarcinoma § B. Colon carcinoma C. Lung adenocarcinoma D. Urinary bladder, mucinous adenocarcinoma E. Colon metastatic to ovary FE. Brea

Slide 12: MVT-5873 Demonstrates Synergistic Anti-Tumor Effect with Chemotherapy
MV7T-5873 DEMONSTRATES SYNERGISTIC ANTI- TUMOR EFFECT WITH CHEMOTHERAPY IN MULTIPLE CANCER MODELS Relative Tumor Growth at Day 42 Relative Tumor Volume at Day 52 Gemcitabine/nab-Paclitaxel as Baseline Paclitaxel as Baseline BxPC3 Pancreatic Xenograft Model us DMS 79 SCLC Xenograft Model Ht gS Soma (

Slide 13: MVT-2163 — HuMab 5B1 as Immuno-PET Imaging Agent
MVT-2163 — HUMAB 5B1 AS IMMUNO-PET IMAGING AGENT ¢@ Significant unmet medical need for improved diagnosis and monitoring of pancreatic cancer @ Preclinical data demonstrate potential for new HuMab-5Bibased PET agent @ Radiolabel abundant, commercially available, relatively inexpensive, & readily ame

Slide 14: MVT-2163 Imaging Compared to Standard Agent in Use Today
MVT-2163 IMAGING COMPARED TO STANDARD AGENT IN USE TODAY Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts Se The co-registration of FDG-PET and computed tomography (CT) (left) and planar sections of FDG-PET only (right) displayed minimal tumor detection of the tracer with

Slide 15: MVT-1075 — Use of HuMab-5B1 in Radioimmunotherapy
MVT-1075 — USE OF HUMAB-5B1 IN RADIOIMMUNOTHERAPY Combines established efficacy of radiation therapy with tumor specific targeting @ Product has potential to deliver more potent HuMab-5B1 based product 177Lu is a low-energy radiation emitter with a relatively short tissue penetration range (maximum,

Slide 16: MVT-1075 Radioimmunotherapy Preclinical Studies Demonstrate Tumor Growth Suppression
MVT-1075 RADIOIMMUNOTHERAPY — PRECLINICAL STUDIES DEMONSTRATE SUBSTANTIAL TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION ia 277Lu-CHX-A"-DTPA-5B1. Biodistribution of !7” Lu-CHX-A”-DTPA-5B1 -@ Control (PBS) = 5B1 oe 75yCi © 150nC > 300uCi © 450nCi 130: 120 110 rs Bth N=8 for all groups y Normalized Tu

Slide 17: HuMab-5B1-Based Antibody Drug Conjugate (ADC)
HUMAB-5B1-BASED ANTIBODY DRUG CONJUGATE (ADC bes 7 2 @ HuMab-5B1 has ideal characteristics ; i for ADC werans seaiaanave @ Antibody is readily internalized Large number of targets on each cell @ Proof of concept already demonstrated Multiple linker/toxin combinations are being evaluated to identify

Slide 18: HuMab-5B1 ADC Demonstrates Efficacy in Multiple Tumor Cell Lines and Animal Models
HUMAB-5B1 ADC DEMONSTRATES EFFICACY IN MULTIPLE TUMOR CELL LINES AND ANIMAL MODELS OF CANCER Internalization of HuMab-5B1 Into Pancreatic Cancer Cells Results in Increased Potency and Killing Effectiveness HuMab-5B1 Antibody Drug Conjugate In Vivo Linker Optimization Study Demonstrates Efficacy —* G

Slide 19: Market Opportunity for HuMab 5B1 — Potential New Treatments in PDAC
MARKET OPPORTUNITY FOR HUMAB 5B1 — REPRESENTS POTENTIAL NEW TREATMENTS IN PDAC Unmet Me ical Need with Large Market PROJECTED CANCER DEATHS Ey wo--- Le pancreas, colorectal roast ----= ° 8 8 [ ] 2010 2020 2010 Www.pancan.org * Fourth leading cause of cancer death - 24 overall by 2020* * 5-year survi

Slide 20: Important First Milestones Achieved in Therapeutic Antibody Phase I Trial
IMPORTANT FIRST MILESTONES ACHIEVED IN THERAPEUTIC ANTIBODY PHASE I TRIAL Monotherapy dose escalation study in locally advanced or metastatic pancreatic cancer patients @ Phase I trial initiated in February 2017 and interim results reported mid-November @ Early safety and tolerability established in

Slide 21: Important First Milestones Achieved in Diagnostic Antibody Phase I Trial
IMPORTANT FIRST MILESTONES ACHIEVED IN DIAGNOSTIC ANTIBODY PHASE I TRIAL MVT-2163 Immuno-PET Diagnostic Agent for Pancreatic Cancer Demonstrates Safety and Proof of Concept in Tumor Visualization @ Next generation diagnostic agent for identification of metastatic lesions, staging of disease, and tre

Slide 22: Status of MVT-1075 Phase I Radioimmunotherapy Clinical Trial
STATUS OF MVT-1075 PHASE I RADIOIMMUNOTHERAPY CLINICAL TRIAL ® Objectives of Phase I trial — Determine MTD and safety profile as a single agent — Determine dosimetry of MVT-1075 — Evaluate tumor response rate and duration of response — Define a recommended Phase II dose as a single agent — Expand Ph

Slide 23: Key Milestones for HuMab5B1 Development Programs for 2016 and 2017
KEY MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAMS FOR 2016 AND 2017 Z _ a cm | aan | Program MVT-5873 Y Initiate dose v Early readout on} * Complete * Full Phase I trial Therapeutic escalation safety safety, PK, dose enrollment result available Monotherapy Phase I Trial MVT-5873 Y Initiate dose Y Ini

Slide 24: Where Do We Go From Here
WHERE DO WE GO FROM HERE Complete monotherapy phase I dose escalation and report results at scientific meeting Complete combination with chemo phase I dose escalation and report results at scientific meeting @ Pilot monotherapy as maintenance therapy in post chemo patients as extension of current ph

Slide 25: Robust Intellectual Property and Knowhow
ROBUST INTELLECTUAL PROPERTY AND KNOWHOW 11 issued patents and 3 pending applications in the U.S. @ Issued patents covering monovalent and polyvalent vaccines, methods of manufacture, methods of use ® 2 pending applications covering monoclonal antibodies 14 international patents and 3 pending applic

Slide 26: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS Management J. David Hansen Founder, President & CEO Board Member Philip Livingston, M.D. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, Ph.D. Founder & Vice President Antibody Discovery Paul Maffuid, Ph.D. Executi

Slide 27: Capitalization Table / Financial Statistics
CAPITALIZATION TABLE/ FINANCIAL STATISTICS Average Security Exercise Price Common Shares - Outstanding - 6.3M Preferred Stock — Common Equivalents _ 30M ($0.01 Liquidation Preference) . Subtotal - 9.3M. Restricted Stock Units — Outstanding and Unvested - 0.2M Warrants - Outstanding $6.84 5.1M Stock

Slide 28: Market Statistics
MARKET STATISTICS* Stock Symbol: MBVX (Nasdaq Capital Market) Closing Price: $3.80 on December 2, 2016 52 Week High/Low: $7.19/$3.04 3-Month Average Daily Volume/Liquidity 123,830/$470,000 Shares Outstanding: 6.3 Million™ Market Cap: $25.3 Million™ Float: 6.0 Million Free Trading Shares *Price & Vol

Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones
DIFFERENTIATED CANCER IMMUNOTHERAPY COMPANY WITH MULTIPLE NEAR-TERM MILESTONES Novel antibody discovery platform producing multiple novel products with significant commercial potential @ Integrated and complementary development strategy leverages antibodies as superior targeting agents Therapeutic a

Slide 30: MabVax Therapeutics Company Contacts
Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts David Hansen Gregory P. Hanson CMA MBA President and CEO Chief Financial Officer dhansen@mabvax.com gtegoryhanson@mabvax.com 858-500-8455 858-500-8457 Media and Investor Relations IRT
Source: SEC EDGAR · 8-K filed Dec 7, 2016
More decks from MabVax Therapeutics Holdings Inc
Investor Presentation (October 2018)19 slides · Oct 22, 2018
Virtual Investor Conference (May 2018)25 slides · May 3, 2018
Investor Presentation (February 2018)24 slides · Feb 12, 2018
Investor Presentation (September 2017)33 slides · Sep 12, 2017
Investor Presentation (August 2017)33 slides · Aug 24, 2017
Investor Presentation (June 2017)23 slides · Jun 23, 2017